Essay On The Worldwide Scattering Of Pharmaceuticals

"In the past two decades or so, health care has been commercialized as never before, and professionalism in medicine seems to be giving way to entrepreneurialism," commented Arnold S. Relman, professor of medicine and social medicine at Harvard Medical School (Wekesser 66). This statement may have a great deal of bearing on reality. The tangled knot of insurers, physicians, drug companies, and hospitals that we call our health system are not as unselfish and focused on the patients' needs as people would like to think. Pharmaceutical companies are particularly ruthless, many of them spending millions of dollars per year to convince doctors to prescribe their drugs and to convince consumers that their specific brand of drug is needed in

Shortages of prescription drugs in the United States are a serious threat to our nation’s health and safety. At first blush, this problem appears fairly simple and straight forward to solve. In reality, there is a complex web of causation with a number of root causes contributing to drug shortages. The aim of this paper is to answer the question: How do we mitigate prescription drug shortages? This discussion is written from the standpoint of advising the current presidential administration how to address this crisis. This essay begins with a discussion regarding the background of the issue. Next, the landscape, including stakeholders in this matter is identified. Following, political, social, economic, and practical factors surrounding

We in America tend to take medications for almost any problem we have, from headaches to gastrointestinal pain, to more serious chronic disorders such as depression and attention deficit disorder. While many of the uses of such medications may be necessary and legitimate, many are not, and due to this fact, many people become dependent on medications, mentally, and or physically. This problem is not simply the fault of the individual; in fact, the blame can also be placed upon the medical community, and the pharmaceutical companies who produce the drugs. How often can one turn on the television to see advertisements for Claritin, Aspirin, Pepto-Bismol, or even Zoloft or Ritalin? The pharmaceutical industry is motivated by monetary

Id. In order for providers to avoid costly claim denials, a risk management and compliance program should be in place and annual monitoring and auditing of internal controls needs to occur on a regular basis. This text will review the issues that medical providers face with coding and billing regulations, the consequences of improper billing and coding, and resolutions that will aid in the prevention of claims being denied.

Competition between providers has caused physicians and hospitals to offer the most current healthcare technologies and modern, eye-catching settings has contributed to increasing healthcare costs, as well as providing unwarranted highly technical services (Shi & Singh, 2015). Renovations of the physical settings and the acquisition of expensive technologies elevated healthcare services prices to cover the additional costs of providing high technical services and attracting clients.

Based on the political and economic environments of states and the federal government the methods of health care reimbursement have been required to evolve. With the introduction of the Patient Protection and Affordable Care Act (PPACA) new laws have been set into place that has caused a stringent review of spending on health care. All care provided is being examined for effectiveness, quality, and the actual need of the service. Unnecessary health care functions are being screened and eliminated. The government and other insurance providers have begun to place cost containment measures in place only paying for those procedures that are deemed medically necessary for the illness that the patient is currently afflicted with. This has a direct impact on the monies that the government and insurance providers will reimburse for services. The following paper will look at the major types of reimbursement activates currently in place. The writer of this paper will also speculate on the future of health care reimbursement and how it will affect his current organization.

Market failure appears when there is a failure in allocation of goods and services. When the market is unsuccessful, the government is called to intervene and correct the failure. Over the years, government participation in the pharmaceutical market has been more wide-ranging than any other good or service. With the government’s ability to regulate, mandate, inform, finance and provide, their intervention to overcome market failure can be beneficial for the economy. Market failure plays a significant role in today’s economy.

The growing non-medical use of prescription drugs is a global health concern. Such usage can be defined as the taking of prescription drugs, whether obtained by prescription or otherwise, other than in the manner or for the reasons or time period prescribed, or by a person for whom the drug was not prescribed. The real scale of the problem is unknown, due to lack of data on the non-medical use of prescription drugs, and to the existence of many gaps in the monitoring of their legal use for medical purposes as pre-scribed by health-care professionals (which creates chances for these drugs to be in the hands of people who they were not prescribed). Most studies on and monitoring instruments for substance abuse pertain to the use of illegal

Additionally, a Marxist approach is one that strives to be action oriented and affect change. Accordingly, a prospective analysis would observe the saturation of painkillers in the American market. With the opioid epidemic formally declared in 2011 as a healthcare crisis in the United States, there is the apprehension surrounding the movement of the sale of OxyContin to target other states where the market has not been oversaturated. If this were to follow the footsteps of other addictive or otherwise controlled substances such as tobacco, then the law of capitalist accumulation acutely captures the expansionist nature of businesses. As Purdue successfully led the charge in opening the American market for painkillers – and we have seen the

As the debate over drug prices heats up, it has rekindled a discussion about the private importation of prescription drugs from other nations. Some politicians like Senator John McCain and Senator Chuck Grassley have advocated for importing drugs directly from Canadian pharmacies. While this would allow Americans to pay a lower price for their medication, the pharmaceutical industry is against such a practice.

Securitization is a process that reinforces what some have and others do not; through the course of this discussion we will focus on access to pharmaceutical drugs as health security. Capitalism enables certain persons, corporations and institutions to take heed of power structures and allows them to reproduce inequality through existing power systems. The production of pharmaceutical drugs takes place in certain regions of the world that paradoxically have hardly any access to them. Once they are produced, it is up to more powerful parties to determine where they will be sent and for how much, directly dictating who will and will not be able to access much needed

Pharmaceutical Sciences is a topic that has interested me for a while now. What I can say about this topic is that it will help humanity grow as a whole and keep everyone moving forward. This is a topic where people really need to think about what goes behind the scenes of your average pharmacies. Once people start to think about it, they would start to realize that the science that happens is extremely crucial to mankind as we know it. Without this kind of science, where would humans be today? Would we have the ability to evolve the way we have? How far would humans make it to creating today’s future as we know it? The simple answer to all these questions is

Yes, there is an impact on the pharmaceutical company, like those in the US as a result of differential prices between that country and other nations.

This report provides an analytical strategic review of the global pharmaceutical industry; its origin, evolution,

Solution: Creating autonomous teams that don’t report into the organization but report to the top management. Co-locate with the local biotech ecosystem. Second, give time bound budgets.